

Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting

Anna R. Moverley, Robin Waxman, Maarten de Wit, Andrew Parkinson, Willemina Campbell, Melanie Brooke, Laure Gossec, and Philip S. Helliwell

ABSTRACT. Objective. The objective of this Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiative is to develop a questionnaire to determine the presence of a flare of disease activity in psoriatic disease (PsD), for use in clinical care and research settings.

Methods. In 2014 and 2015, 2 online Delphi surveys of patients and physicians attempted to achieve consensus about items that might discriminate a flare of disease. In the first round, items were derived from previous qualitative studies with patients; in the second round, new items, suggested by both patients and physicians, were added. Survey results were discussed at the 2015 GRAPPA annual meeting, and 8 breakout groups discussed specific aspects of PsD flares.

Results. Survey participants were patients (n = 103 and n = 57 in rounds 1 and 2) and physicians (n = 125 and n = 81). Items for flare covered 6 domains (joints, skin, emotion, participation, fatigue, and unclassified). Patients agreed that 20 items were important (10 joints, 1 participation, 8 fatigue, 1 unclassified), and physicians agreed on 23 items (5 skin, 11 joints, 4 participation, 3 unclassified). Eight items were selected as important by both groups: 7 joint items and 1 unclassified. Patients emphasized fatigue and physicians emphasized skin and participation. Breakout groups concluded that the components of a flare instrument should be derived from patients. A flare should be defined as a change in disease state requiring intervention.

Conclusion. The concept of flare in PsD covers articular, skin, emotional, participation, and fatigue domains. Further work is required to specify items that represent these domains. (J Rheumatol 2016;43:974–8; doi:10.3899/jrheum.160118)

Key Indexing Terms:

PSORIATIC ARTHRITIS

PSORIASIS

DISEASE FLARE

GRAPPA

From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.

Funded in part by The Psoriasis and Psoriatic Arthritis Alliance, UK. The work of A.R. Moverley was funded in part by a grant from Arthritis Research UK.

A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.

Address correspondence to Dr. P.S. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Harehills Lane, Leeds LS7 4SA, UK. E-mail p.helliwell@leeds.ac.uk

Psoriatic arthritis (PsA) and psoriasis are chronic disabling conditions with common pathogenic mechanisms¹. Together with associated comorbidities, they form part of what is known as psoriatic disease (PsD). The core elements assessed in PsA clinical trials include peripheral joint activity, skin activity, patient's global assessment, pain, physical function, and health-related quality of life². Items thought to be important in assessment but not part of the core set include enthesitis, dactylitis, nail and spinal disease, fatigue, physician's global assessment, and radiology. The domains of impact vary between physician and patient perspectives; patients identify as the top 3 pain, fatigue, and skin symptoms³. Further development is ongoing of the core set of domains and the composite measures that include them^{4,5}.

As mentioned, disease activity may not be sufficiently described using only the core set. Indeed, patients often describe a flare of their disease, which they describe as something that is experienced beyond just the physical symptoms of the disease. In a recent qualitative study, patients identified 9 overarching themes pertaining to flare: physical symptoms, social withdrawal, psychological symptoms, fatigue, loss of normal function, triggers, management of pre-flare, management of flare, and timing⁶.

Emotional and psychological items also appeared as important domains of impact in another study that used the patient perspective⁷.

No measures have been validated to assess disease flare in PsD. A systematic literature review in 2011 found only 5 articles relating to flare in PsA. Most studies analyzed the inverse, or absence, of a disease target, such as remission or low disease activity⁷. Similar studies assessing the prevalence of flare after treatment tapering and withdrawal have identified the absence of low disease activity as the definition of flare^{8,9}.

The purpose of the current study is to develop an instrument that can be used to determine the presence of a flare of disease activity in PsD. The study builds on previous qualitative work to further refine a definition of flare primarily from the patient's point of view. In collaboration with the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), surveys of both patients and physicians were undertaken and discussed at the GRAPPA annual meeting in July 2015.

MATERIALS AND METHODS

Full ethical approval was obtained for our study (UK National Research Ethics Service Committee Yorkshire and The Humber — Bradford Leeds: 12/YH/0041).

The process to develop a flare questionnaire comprised several steps.

Initial list of discriminatory items that would be part of a flare instrument. These items were obtained from a qualitative interview study⁶ in which 18 patients were interviewed about their experiences of flare. Transcripts were analyzed and items coded into 9 overarching themes: physical symptoms, triggers, management of pre-flare, social withdrawal, fatigue, loss of normal function, psychological symptoms, timing, and management of flare.

Delphi surveys. The first survey was conducted on the Internet using SurveyMonkey software (www.surveymonkey.com) between September and December 2014. The purpose of the survey was to obtain consensus among patients as well as physicians on the important and discriminatory items that would be part of a flare instrument. The wording of items obtained in the patient interviews was retained. Respondents were asked to rate the ability of each item to identify a flare, and were asked to consider a recent change or increase in that item. The response options were a numerical rating scale with 9 points, from 1 (not discriminating at all) to 9 (extremely discriminating). Respondents were also offered a "don't know" option. Items were presented under 5 general headings: skin (13 items), joints (19 items), emotional (16 items), participation (13 items), fatigue (8 items). There was also an unclassified heading (10 items). If 70% or more of respondents in 1 group graded the item as 6 or above, then the item was deemed to be accepted by the respondents of that group as a discriminating item for flare. Similarly, if 70% graded the item as 5 or below, the item was regarded as not discriminating, and removed. A free text field was available for comments and suggestions for items that were thought to be important but missing.

Using the results of the first survey, a second survey with a reduced item set was used for both physicians and patients. From the first survey, items were omitted that achieved consensus (either to remove, or to include) by the physicians. This enabled us to send only 1 further survey, rather than 2 different surveys (1 to patients and 1 to physicians). Further, the mean response score (appropriately for patients and physicians) from the first survey was included with each item as a guide for respondents, who were encouraged to vote at the extremes of response. In addition, new items suggested in the free text field of the first survey were also included. The

surveys were all in English and were identical for both physicians and patients.

The physician group comprised the membership of GRAPPA, a worldwide organization with about 500 members, roughly one-third dermatologists and two-thirds rheumatologists. A small number of patients [the GRAPPA patient research partners (PRP)] also responded in this cohort but the responses were transferred to the patients' survey results. The patient groups comprised members of the Psoriasis and Psoriatic Arthritis Alliance, an organization in the United Kingdom with over 5000 members (www.papaa.org). Patients were invited to complete the survey online by a link available on the organization's website, as well as by mention in the society newsletter. Patients were also included from a second patient organization, also based in the United Kingdom, which has a smaller membership of about 100 (PsAZZ Psoriatic Arthritis Support Group, psazzgroup.wix.com/psazz).

Face-to-face discussion. The results of the surveys were presented at the GRAPPA annual meeting in Stockholm in July 2015. Following plenary presentations, members (175 registrants: 10 patients, 108 physicians, 25 trainee physicians, and 32 industry partners) divided into 8 breakout groups of about 20 participants each. Each group included a GRAPPA PRP¹⁰, an even distribution of dermatologists and rheumatologists, a proportion of trainees, and a facilitator. Each group addressed a specific topic: symptom duration to define a flare; objective signs and change values defining a flare; final use of a flare questionnaire as a physician questionnaire or patient-reported-only questionnaire; and use in clinical practice or research of a flare questionnaire. Each group also specifically discussed a domain from the survey, the latter using the nominal group technique in which each individual "silently" pre-ranked the items. The results of the discussions were presented in a final GRAPPA plenary session.

RESULTS

Survey. The demographics of the respondents to each survey are provided in Table 1.

One hundred three patients responded to the initial survey and 57 to the second survey; 125 and 81 physicians responded to the first and second surveys, respectively. There were 79 items in the first survey and 53 in the second. The results of the surveys (items accepted or rejected) are given separately for patients and physicians in Table 2, in which the items accepted and rejected are highlighted (individual item responses to the first and second round are given in the Supplementary Tables, available online at jrheum.org). Twelve new items were suggested by respondents to the first survey, and patients and physicians agreed that 2 of these (joint swelling and night pain) were important in the second survey.

As a result of this exercise, a total of 20 items were agreed on as important by patients (10 joints, 1 participation, 8 fatigue, 1 unclassified), and 23 items by physicians (5 skin, 11 joints, 4 participation, 3 unclassified). Eight of these items (7 joint items and 1 unclassified) were accepted by both groups:

1. A recent change in joint pain.
2. A recent change in location of symptoms (i.e., sudden increase in pain or swelling in hands/feet).
3. A recent change in the number of tender and/or sore joints.
4. A recent change in the number of aching joints.
5. The presence or degree of pressure-sensitive joints.
6. A recent change/increase in the number of swollen joints.
7. A recent change/increase in night pain.

Table 1. Demographics of the respondents to the surveys.

	Physicians		Patients	
	First Survey	Second Survey	First Survey	Second Survey
N	125	81	103	57
Age, yrs, mean	49	49	55*	57*
Sex, n (%)				
Male	86 (69)	59 (73)	26 (25)	11 (19)
Female	39 (31)	22 (27)	77 (75)	46 (81)
Specialty, n (%)			N/A	N/A
Rheumatology	96 (77)	62 (77)		
Dermatology	29 (23)	19 (23)		
Patients, n (%)	N/A	N/A		
Psoriasis			8 (8)	2 (3)
Psoriatic arthritis			95 (92)	55 (97)

* Approximate mean age; patients were asked only to designate an age range. N/A: not applicable.

Table 2A. Number of items accepted and rejected, by domain and respondent, in survey 1.

	No. Items	Survey 1		Survey 1		Agreement between	
		Patients		Physicians		Patients and Physicians	
		Accept*	Reject [#]	Accept*	Reject [#]	Accept	Reject
Skin	13	0	6	0	2	0	2
Joints	19	5	1	8	2	4	1
Emotional	16	0	4	0	13	0	3
Participation	13	0	1	4	5	0	1
Fatigue	8	7	0	0	0	0	0
Miscellaneous	10	0	3	1	3	0	1
Total	79						

*Based on $\geq 70\%$ recording 6 or more. [#] Based on $\geq 70\%$ recording 5 or fewer.

Table 2B. Number of items accepted and rejected, by domain and respondent, in survey 2.

	No. Items from Survey 1 (plus new items)	Survey 2		Survey 2		Agreement between	
		Patients		Physicians		Patients and Physicians	
		Accept	Reject	Accept	Reject	Accept	Reject
Skin	11 (+5)	0	4	5	6	0	4
Joints	9 (+4)	7	0	3	0	3	0
Emotional	3 (+2)	0	2	0	5	0	2
Participation	4 (+1)	1	0	0	0	0	0
Fatigue	8	8	0	0	1	0	0
Miscellaneous	6	1	0	2	0	1	0
Total (includes new items)	53						

8. A recent change/increase in the number or combination of symptoms.

Breakout group discussion. In discussing symptom duration, flare was defined as a change in disease state that necessitates a change in treatment or as a marked worsening of ability to continue with activities of daily living. Flare was regarded as short-lived and acute as distinguished from worsening of disease, which is slower and longer-lived. A flare would take the form of hours to days of worsening of joints and days to weeks of worsening of skin.

A mapping exercise was suggested so that any flare instrument would be related to objective signs and change values of other patient-reported instruments, such as the Psoriatic Arthritis Quality of Life instrument¹¹, the Psoriatic Arthritis Impact of Disease instrument³, the Medical Outcomes Study Short Form-36, the Health Assessment Questionnaire¹², and the Routine Assessment of Patient Index Data 3¹³, as well as to objective measures of disease activity such as the Psoriasis Area and Severity Index¹⁴ or Body Surface Area for skin; joint counts; and measures of axial

disease, enthesitis, and dactylitis. Groups also considered the relationship of flare instrument to global visual analog scale (both patient and physician) scores.

It was agreed that a flare instrument should be a patient-reported outcome developed in collaboration with physicians.

In general, it was thought that instruments for both clinical practice and research should be available. However, the use of an instrument as a research or clinical tool would alter the cutoff for sensitivity or specificity of the instrument. No clear consensus was achieved on the duration of symptoms, but a flare could be defined as a change in disease state requiring intervention. A flare instrument could be mapped to many objective signs and change values. No decision was confirmed during this meeting about whether a flare instrument should be exclusively for clinical or research use.

A number of groups chose 5 key questions to measure a domain. Generally, the groups thought too many joint items were included in the survey, and many of the questions were similar; however, with regard to joint aspects of flare, the 5 key questions were joint pain, swollen joints, morning stiffness, location, and number of joints.

Group members identified the need for further work on skin symptomatology, with some emphasis also on widening the survey to patients in other countries and other cultures. They emphasized a few key points related to skin symptoms: area of skin involvement, itching of skin, and redness/heat of skin. The groups decided that participation could be covered by 5 key questions: ability to do normal activities, motivation and concentration, quality of life, ability to move easily, and relationships. They decided that emotion is subject to cultural differences, making it hard to generalize internationally.

Fatigue was discussed as the most important symptom of flare because it serves both as a marker of a prodrome (to meaningful symptom change) and as a lag phase after the flare has been treated. Groups confirmed that flare was distinguishable from other causes of fatigue (such as jet lag and postoperative fatigue), and that fatigue was culturally variable. Further, it was suggested that fatigue should be differentiated from other causes of symptoms, such as fibromyalgia (FM); however, if this means physicians have to rule out FM, it may be short-sighted because fatigue is a complaint of many members of the PRP group and other patients with PsA.

From the 12 unclassified items in the original Delphi survey, those ranked in the top 5 were retained. Among the 5 items retained were, ranked in this order, self-reported flare, combination/number of symptoms, duration of symptoms, flu-like symptoms, and self-medication.

DISCUSSION

In this study, we report further work toward development of a patient-reported instrument to measure flare in PsD. The results show a clear discrepancy between patients and physi-

cians in items deemed discriminatory for a flare of the disease, with patients placing more emphasis on fatigue items and physicians more emphasis on participation. Both groups agreed on 7 joint items and 1 skin item. Discussions in small groups further refined what a flare instrument should be, but more work is needed on the individual items. It is important to keep any instrument feasible and suitable for use in the clinic and research settings.

What can be said about a flare in PsD from the point of view of a patient? It is clear that it encompasses not only physical items, such as joints and skin, but also items such as emotion, fatigue, and participation. Indeed, the temporal relationship of these items to flare may vary — fatigue may precede the worsening of joints and skin, and fatigue and participation may take longer to resolve after the flare is controlled. It is also important to note that the decision to develop a patient-reported measure of flare will exclude objective measures of disease such as joint counts and skin assessments. However, the validation phase of the measure will include mapping onto these objective signs, as well as onto other patient-reported outcomes.

A challenge in developing a flare instrument will be the heterogeneity of the disease. For example, a patient may experience a flare of the skin but not the musculoskeletal manifestations. Alternatively, the patient may have an isolated flare of enthesitis, such as pain in the heel, or axial pain. The ability of a flare instrument to capture this adequately will require careful study. There is also the question of degrees of flare severity. A patient may appropriately self-manage a mild flare, but need a change in medication for a severe one.

An alternative challenge, and a limitation of our current study, is the divergence between patients and physicians in the selection of items that might be discriminative for a flare. In the first survey, discordance was demonstrated; if we had sent 2 separate surveys for the second round, we would have only further increased these disparate views. Although this disparity was not resolved ideally, we chose to send the same items to both patients and physicians for the second survey, which helped provide some degree of consensus, albeit a minimal one.

A further limitation of our current study is whether the patient population surveyed is representative. The international membership of GRAPPA ensured a global perspective for physician input. However, because cultural and ethnic concerns could possibly influence responses, it is important to ensure that patients from different countries are surveyed as the work proceeds.

One of the drivers to develop a flare instrument has been the success of biological therapies in PsD. As patients enter low disease activity, the possibility of stopping the drug appears, because early remission may have caused a change in disease status. Of the 3 main treatment withdrawal studies to date, the main outcome has been an absence of the

remission (or low disease activity) state, rather than a true measure of flare of the disease^{8,9,15}. An instrument to measure flare will be of use in these situations, as well as measuring disease status in the clinic. Ultimately, the relationship between patient-reported flare and composite measures of disease activity will be of interest, although existing composite measures do include patient-reported outcomes. Thus components of a flare instrument may eventually be incorporated into such instruments⁵.

The development of a flare instrument for PsA should be considered alongside a similar effort in rheumatoid arthritis (RA) that has been under way for more than 4 years. A qualitative study in self-management strategies of patients with RA showed that flare is variably characterized by patients as stiffness, swelling, and pain¹⁶. This RA study was primarily conducted to explore some variations with ethnicity on attributing cause of flare and how to manage a flare, providing further useful information from the patient's perspective on ethnic variants and variability¹⁶. Disease flare definition may also depend on a patient's duration of disease¹⁷, and patients have reflected that experience comes with longer disease duration¹⁸. Patients also describe how the relative importance of pain and mobility change over time, with pain being a consistent problem in flare throughout disease, and changes in mobility coming later¹⁷. In parallel, a French group has developed a self-administered questionnaire to identify past or present rheumatoid flare — the FLARE questionnaire¹⁹. Much work from RA can be adapted for use in PsA because of similarities in the articular disease; however, it is necessary to address further domains of the disease as outlined above and with reference to the inner, outer, and peripheral circles of the Outcome Measures in Rheumatology (OMERACT) core set for PsA².

The concept of flare in PsD covers articular, skin, fatigue, emotional, and participation domains. The search is ongoing for specific items to represent these domains and will include further consensus exercises to rank items in order of importance. Existing databases also must be explored to validate any proposed measure.

ACKNOWLEDGMENT

The authors thank David Chandler, chief executive of Psoriasis and Psoriatic Arthritis Alliance, for his assistance with this project, and the participating patients for their involvement in our study.

ONLINE SUPPLEMENT

Supplementary data for this article are available online at jrheum.org.

REFERENCES

- Boehncke WH, Schon MP. Psoriasis. *Lancet* 2015;386:983-94.
- Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. *J Rheumatol* 2007;34:1167-70.
- Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scriver R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis* 2014;73:1012-9.
- Tillett W, Adebajo A, Brooke M, Campbell W, Coates LC, FitzGerald O, et al. Patient involvement in outcome measures for psoriatic arthritis. *Curr Rheumatol Rep* 2014;16:418.
- Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. *J Rheumatol* 2014;41:1212-7.
- Moverley AR, Vinall-Collier KA, Helliwell PS. It's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. *Rheumatology* 2015;54:1448-53.
- Caperon A, Helliwell PS. Remission in psoriatic arthritis. *J Rheumatol Suppl.* 2012 Jul;89:19-21.
- Moverley A, Coates L, Marzo-Ortega H, Waxman R, Torgerson D, Cocks K, et al. A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic Arthritis (RETREAT (F))). *Clin Rheumatol* 2015;34:1407-12.
- Araujo EG, Finzel S, Englbrecht M, Schreiber DA, Faustini F, Hueber A, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. *Ann Rheum Dis* 2015;74:655-60.
- Cheung PP, de Wit M, Bingham CO 3rd, Kirwan JR, Leong A, March LM, et al. Recommendations for the involvement of patient research partners (PRP) in OMERACT working groups. A report from the OMERACT 2014 Working Group on PRP. *J Rheumatol* 2016;43:187-93.
- McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. *Ann Rheum Dis* 2004;63:162-9.
- Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 1986;25:206-9.
- Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. *J Rheumatol* 2008;35:2136-47.
- Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. *Dermatologica* 1978;157:238-44.
- Chimenti MS, Esposito M, Giunta A, Graceffa D, Babino G, Teoli M, et al. Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse. *Int J Immunopathol Pharmacol* 2013;26:833-8.
- Kett C, Flint J, Openshaw M, Raza K, Kumar K. Self-management strategies used during flares of rheumatoid arthritis in an ethnically diverse population. *Musculoskeletal Care* 2010;8:204-14.
- Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient's perspective. *J Rheumatol* 2003;30:880-3.
- Bingham CO 3rd, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, et al. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). *J Rheumatol* 2009;36:2335-41.
- Berthelot JM, De Bandt M, Morel J, Benatig F, Constantin A, Gaudin P, et al. A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument. *Ann Rheum Dis* 2012;71:1110-6.